Treatment Options: Why Medical Therapy is Standard
At a Glance
Familial hyperaldosteronism type IV is usually managed with aldosterone-blocking medicines rather than adrenal surgery because the genetic change can affect both glands. Treatment is adjusted using blood pressure, potassium, kidney function, and renin monitoring.
Managing Familial Hyperaldosteronism Type IV (FH4) requires a different approach than the more common forms of adrenal disease. In many adult cases of high aldosterone, surgery to remove a single gland can offer a cure. However, because FH4 is a genetic condition affecting every cell in both adrenal glands, the approach is generally medical rather than surgical [1]. The goal of treatment is to protect your child’s heart, kidneys, and blood vessels by neutralizing the effects of the extra aldosterone.
Why Surgery is Not Generally Recommended
In FH4, the adrenal glands often look normal on a CT scan, or they may show small bumps that can be misleading [1]. Because the CACNA1H variant is a germline issue (present in the DNA of every cell), the overproduction of aldosterone isn’t limited to one spot or one tumor [2].
- Ineffectiveness: Removing one adrenal gland (unilateral adrenalectomy) is generally avoided for FH4. Research shows that patients who undergo unilateral surgery often see their high blood pressure and hormone imbalances return shortly after because the variant is active in both glands [1]. A CACNA1H result alone does not prove that every patient has bilateral functional disease, but surgery requires specialist review and functional localization (AVS) if it is being considered.
- A “Systemic” Problem: Doctors view FH4 as a systemic adrenal channelopathy. Removing one gland simply leaves the other gland to continue the same overproduction [3][1].
- Avoiding Adrenal Insufficiency: Removing both glands (bilateral adrenalectomy) is a drastic step that requires lifelong hormone replacement therapy for multiple other essential hormones (like cortisol). Medical therapy is preferred to avoid this complication [4].
Cornerstone Medical Therapies
The primary goal of medication is to block the aldosterone that the body is over-producing.
Mineralocorticoid Receptor Antagonists (MRAs)
These are the most important medications for FH4. They sit on the “lock” (the receptor) that aldosterone tries to turn, preventing the hormone from raising blood pressure or flushing out potassium [5].
- Spironolactone: This is a common and effective choice, but it can sometimes cause side effects like breast tenderness or hormone changes during puberty [6].
- Eplerenone: This is a newer, more selective MRA. While it may need to be taken more frequently (often twice a day), it is often better tolerated and has fewer hormonal side effects [7][6].
MRA Safety Warnings: Spironolactone and eplerenone carry important risks. They can cause high potassium (hyperkalemia), worsen kidney function, and cause dehydration or excessively low blood pressure. Never start, stop, or change an MRA, potassium supplement, ACE inhibitor, or NSAID (like ibuprofen) without your clinician’s advice. You must avoid potassium-containing salt substitutes entirely, as they can cause lethal hyperkalemia. Call your doctor urgently for marked weakness, palpitations, fainting, or reduced urine output.
Calcium Channel Blockers (CCBs)
Standard calcium channel blockers are often used alongside MRAs for general blood pressure control. Since the underlying problem in FH4 is an altered calcium channel (CaV3.2 T-type), adding a specific T-type calcium channel blocker has been discussed in research [1].
- L-type vs. T-type: Most common blood pressure medications (like amlodipine) target L-type channels. However, because FH4 specifically involves T-type channels, some researchers have considered “dual” blockers (like efonidipine) [1][8]. Note that this is an experimental, off-label strategy; it is not an established standard treatment, may be unavailable, and should not replace MRA therapy. It requires an endocrinologist’s oversight.
Monitoring Success: The Role of Renin
In FH4, the excess aldosterone “suppresses” or turns off your child’s renin (a protein made by the kidneys). One of the signs that the medication is working is renin un-suppression [9].
- The Renin Marker: When the medication dose is high enough to block the extra aldosterone, the kidneys will start making renin again [10][9]. Renin is one specialist-guided marker, but it is influenced by posture, age, and diet, so never adjust your own treatment based on a single renin lab value.
- Blood Pressure and Potassium: Treatment also aims for age-appropriate blood pressure, stable kidney function, and normal potassium levels without the need for constant potassium supplements [11][12].
Regular blood work (especially potassium and creatinine checks shortly after starting or changing a dose) and home blood pressure monitoring are essential to “fine-tune” these doses as your child grows and develops [12]. Lowering salt (sodium) in the diet safely without salt substitutes can also help these medications work more efficiently [9].
Common questions in this guide
Why is medication usually preferred over adrenal surgery for FH4?
Which medicines are commonly used to control FH4?
How will doctors know whether my child's FH4 treatment is working?
What should we avoid while my child takes spironolactone or eplerenone?
Can calcium channel blockers replace spironolactone or eplerenone for FH4?
What side effects should we watch for with FH4 medicines?
Get notified when new evidence is published on Familial hyperaldosteronism type IV.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Familial Hyperaldosteronism Type IV (FH-IV)-Clinical Phenotypes, Genetics and Management of CACNA1H-Related Primary Aldosteronism: A Systematic Review.
Michalski W, Jaszczyszyn I, Bielska W, Stolarczyk A
Journal of clinical medicine 2026; (15(10)) doi:10.3390/jcm15103693.
PMID: 42194655 - 2
Update on the Genetics of Primary Aldosteronism and Aldosterone-Producing Adenomas.
Pitsava G, Faucz FR, Stratakis CA, Hannah-Shmouni F
Current cardiology reports 2022; (24(9)):1189-1195 doi:10.1007/s11886-022-01735-z.
PMID: 35841527 - 3
Enhanced Ca2+ signaling, mild primary aldosteronism, and hypertension in a familial hyperaldosteronism mouse model (Cacna1h ).
Seidel E, Schewe J, Zhang J, et al.
Proceedings of the National Academy of Sciences of the United States of America 2021; (118(17)) doi:10.1073/pnas.2014876118.
PMID: 33879608 - 4
Primary aldosteronism and long-term outcomes using PAMO definition.
Chu WK, Lai CF, Chiang S, et al.
Hypertension research : official journal of the Japanese Society of Hypertension 2026; (49(2)):457-468 doi:10.1038/s41440-025-02324-7.
PMID: 40804167 - 5
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.
Adler GK, Stowasser M, Correa RR, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(9)):2453-2495 doi:10.1210/clinem/dgaf284.
PMID: 40658480 - 6
Efficacy and safety of medical treatment of primary aldosteronism: a real-world data study in Spain.
Goi J, Paja Fano M, Rizo Gellida A, et al.
European journal of endocrinology 2025; (193(2)):297-309 doi:10.1093/ejendo/lvaf158.
PMID: 40743244 - 7
Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.
Karashima S, Yoneda T, Kometani M, et al.
Hypertension research : official journal of the Japanese Society of Hypertension 2016; (39(3)):133-7 doi:10.1038/hr.2015.129.
PMID: 26606875 - 8
Recurrent CACNA1HE282K is a gain-of-function mutation associated with primary hyperaldosteronism.
Li R, Jiang Y, Chen Q, et al.
European journal of endocrinology 2026; (194(1)):22-34 doi:10.1093/ejendo/lvaf253.
PMID: 41403024 - 9
Biomarkers to Guide Medical Therapy in Primary Aldosteronism.
Hundemer GL, Leung AA, Kline GA, et al.
Endocrine reviews 2024; (45(1)):69-94 doi:10.1210/endrev/bnad024.
PMID: 37439256 - 10
Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis.
Katsuragawa S, Le MV, Fuller PJ, Yang J
The lancet. Diabetes & endocrinology 2025; (13(12)):1041-1053 doi:10.1016/S2213-8587(25)00263-3.
PMID: 41235994 - 11
Treatment of Primary Aldosteronism.
Parisien-La Salle S, Hundemer GL, Nehs MA, et al.
Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26238 doi:10.1161/HYPERTENSIONAHA.126.26238.
PMID: 41808633 - 12
Primary aldosteronism.
Vaidya A, Kline GA, Mulatero P, et al.
Nature reviews. Disease primers 2026; (12(1)).
PMID: 42350437
This page is for informational purposes only and does not constitute medical advice. Treatment choices and medication changes for a child with FH4 should be guided by their endocrinology team.